Our Expert Network

31. The Missing Partners In microRNA Silencing: What QKI Reveals About RNA Regulatory Complexity 6/26/2026

    New research suggests microRNA silencing depends on RNA-binding protein partners like QKI, revealing a more complex regulatory network shaping gene expression.

32. RNA Therapeutics: Why CMC Strategy Will Define The Next Decade 6/25/2026

    As RNA matures into an industrial platform, long-term success will depend less on discovery and more on scalable CMC systems, integration, and execution.

33. Rethinking The Oligonucleotide Backbone: Why RNA Therapeutics May Need A New Molecular Design Framework 6/24/2026

    New backbone chemistries could unlock greater control over delivery, specificity, and safety, expanding the molecular design space for RNA medicines.

34. RNA Platforms: What Transfers And What Breaks 6/23/2026

    A practical framework for distinguishing reusable RNA platform knowledge from biology-specific unknowns as therapeutics expand into new tissues and indications.

35. The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of Therapeutics 6/19/2026

    Long non-coding RNAs and splicing networks are emerging as master regulators of cellular identity, opening new therapeutic opportunities beyond proteins.

36. RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease Biology 6/18/2026

    RNA-binding proteins orchestrate splicing, stability, localization, and translation, emerging as powerful regulators and therapeutic targets in disease.

37. Beyond The Liver: How Machine Learning-Optimized LNPs Are Expanding RNA Delivery Into Adipose Tissue 6/8/2026

    Machine learning-guided LNP design is enabling targeted RNA delivery to adipose tissue, opening new possibilities for obesity, metabolic disease, and beyond.

38. Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi Therapeutics 6/8/2026

    As siRNA design matures, the next breakthroughs will depend on balancing chemical optimization, delivery challenges, and expanding beyond established design rules.

39. Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2) 6/4/2026

    Part 2 explores the downstream technologies that turn RNA into a therapeutic product, from impurity removal and LNP formulation to GMP infrastructure and scalable manufacturing.

40. From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS Repair 6/1/2026

    Exosomes are biological vesicles used for cellular communication that can overcome CNS barriers, delivering therapeutic cargo for CNS and optic nerve injuries.